At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
Bimekizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
In Brief
A Phase 2 clinical trial evaluating Bimekizumab, Adalimumab, and 1 other intervention for Hidradenitis Suppurativa. Completed, enrolled 90 participants across 31 sites in 8 countries.
Detailed Summary
Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHidradenitis Suppurativa
CountriesAustralia, Belgium, Denmark, Germany, Greece, Norway, Russia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartSep 2017
Primary CompletionNov 2018
Study CompletionFeb 2019
TodayJul 2026
First PostedAug 14, 2017
Enrollment StartSep 22, 2017
Primary CompletionNov 23, 2018
Study CompletionFeb 21, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.9 years ago
Interventions
Bimekizumabdrug
Bimekizumab in different dosages (dose 1 and 2).
Adalimumabdrug
Adalimumab in different dosages (dose 1, 2 and 3).
Placeboother
Placebo will be provided matching Bimekizumab.